Tag Archives: postpartum depression fda

Booming Postpartum Depression Management Market Predicted: Projected CAGR of 3.8% to Propel Market to US$ 173.9 Million by 2032

The global Postpartum Depression Management Market is expected to grow at a 3.8% CAGR, with a revenue share of US$ 115.1 million in 2022, rising to US$ 173.9 million by 2032. Postpartum Depression Management market players: SAGE Therapeutics Inc., Cipla Limited, Sun Pharmaceutical Industries Ltd., Anikem Laboratories, Intas Pharmaceuticals Ltd., Mylan N.V., among others represent the global Postpartum Depression Management market. The market …

Continue reading “Booming Postpartum Depression Management Market Predicted: Projected CAGR of 3.8% to Propel Market to US$ 173.9 Million by 2032”